Related references
Note: Only part of the references are listed.Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening
David Bajusz et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
InChI, the IUPAC International Chemical Identifier
Stephen R. Heller et al.
JOURNAL OF CHEMINFORMATICS (2015)
The future of JAK inhibition in myelofibrosis and beyond
John O. Mascarenhas et al.
BLOOD REVIEWS (2014)
Selective JAK inhibitors in development for rheumatoid arthritis
Peter Norman
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Selective JAK inhibitors
Brian W. Dymock et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Luzhou Xing et al.
NATURE MEDICINE (2014)
Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis
Martin E. Dowty et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential
Maurizio Cutolo
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2013)
Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: Significance of the para-hydroxyl orientation
Rebekah Baskin et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
J. Mascarenhas et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Selective JAK1 inhibitor and selective Tyk2 inhibitor patents
Peter Norman
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
ChemProspector and generic structures: advanced mining and searching of chemical content
Valentina Eigner-Pitto et al.
Journal of Cheminformatics (2012)
ROCK and JAK1 Signaling Cooperate to Control Actomyosin Contractility in Tumor Cells and Stroma
Victoria Sanz-Moreno et al.
CANCER CELL (2011)
The Stilbenoid Tyrosine Kinase Inhibitor, G6, Suppresses Jak2-V617F-mediated Human Pathological Cell Growth in Vitro and in Vivo
Annet Kirabo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ
Geoff M. Gordon et al.
BIOCHEMICAL JOURNAL (2010)
Structure-Function Correlation of G6, a Novel Small Molecule Inhibitor of Jak2 INDISPENSABILITY OF THE STILBENOID CORE
Anurima Majumder et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening
Robert Kiss et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
Neal K. Williams et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers
Eun Goo Jeong et al.
CLINICAL CANCER RESEARCH (2008)
Jak2: normal function and role in hematopoietic disorders
James N. Ihle et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
Ba/F3 cells and their use in kinase drug discovery
Markus Warmuth et al.
CURRENT OPINION IN ONCOLOGY (2007)
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation - Cross-talk with IGF1 receptor
J Staerk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Share Paper
